Results 91 to 100 of about 385 (131)

Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. [PDF]

Eur Heart J Cardiovasc Pharmacother
Awad K, Pereyra Pietri M, Farina JM, Pathangey G, Abbas MT, Scalia IG, Le Couteur D, Wilanksy S, Lester SJ, Ommen SR, Geske JB, Arsanjani R, Ayoub C.   +12 more
europepmc   +1 more source

Cardiac myosin inhibitors: a silver lining for an old disease. [PDF]

Open Heart
Yadav S, Agstam S, Singh S.
europepmc   +1 more source

Hypertrophic Cardiomyopathy and Phenocopies: New Therapies for Old Diseases-Current Evidence and Future Perspectives. [PDF]

J Clin Med
Alfarano M, Ciccarelli F, Marchionni G, Ballatore F, Costantino J, Lattanzio A, Pecci G, Stavagna S, Iannelli L, Galardo G, Lavalle C, Miraldi F, Vizza CD, Chimenti C.   +13 more
europepmc   +1 more source

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology, 2023
Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in-class cardiac myosin inhibitor, may lower gradients and improve symptoms in these patients.This study aims to evaluate the safety and efficacy of aficamten in patients with oHCM ...
Albree Tower-Rader, Theodore Abraham, Timothy C Wong   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Echocardiographic Changes With Aficamten

Journal of the American College of Cardiology
Milind Desai
exaly   +2 more sources

Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

American Journal of Cardiovascular Drugs, 2023
Aficamten is a novel cardiac myosin inhibitor that has demonstrated its ability to safely lower left ventricular outflow tract (LVOT) gradients and improve heart failure symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM). Based on the REDWOOD-HCM open label extension (OLE) study, participants receiving aficamten had significantly ...
Sneha Annie Sebastian, Inderbir Padda, Eric J. Lehr, Gurpreet Johal   +3 more
openaire   +2 more sources

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure
Albree Tower-Rader, Michael Nassif, Lisa Meng   +2 more
exaly   +2 more sources

Aficamten in Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Michelle Kittleson
exaly   +2 more sources

Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy

Journal of the American College of Cardiology
Background: Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by left ventricular (LV) hypertrophy, LV outflow tract obstruction, and left atrial dilation, which can be associated with progressive heart failure, atrial fibrillation, and stroke. Aficamten is a next-in-class cardiac myosin inhibitor that reduces outflow tract obstruction by
, Sheila Hegde, Matthew Lee
exaly   +2 more sources